Provider Briefing: Balcoltra 28 Day Availability in 2026

As a prescriber, you may be fielding calls from patients who can't fill their Balcoltra 28 Day prescriptions. This briefing summarizes the current supply landscape, generic developments, clinical alternatives, and tools you can use to help your patients maintain uninterrupted contraception.

Balcoltra (levonorgestrel 0.1 mg/ethinyl estradiol 0.02 mg tablets with ferrous bisglycinate 36.5 mg placebo tablets) is a low-dose monophasic combined oral contraceptive manufactured by Avion Pharmaceuticals, LLC. It was FDA-approved on January 9, 2018.

Current Supply Timeline

Key milestones in Balcoltra's availability landscape:

• January 2018: FDA approval of Balcoltra (Avion Pharmaceuticals)
• August 2023: FDA approval of generic version by Xiromed (marketed as Joyeaux) — contains ferrous fumarate 75 mg in placebo tablets instead of ferrous bisglycinate 36.5 mg
• February 2024: FDA approval of second generic version by Lupin Ltd
• March 2026 (current): Balcoltra is not listed on the FDA Drug Shortage database. However, real-world pharmacy availability remains inconsistent, particularly at chain pharmacies

The emergence of two FDA-approved generics should theoretically improve access, but actual pharmacy stocking of these generics has been gradual.

Prescribing Implications

When patients report difficulty filling their Balcoltra prescription, consider the following clinical factors:

Therapeutic Equivalence

Both approved generics (Xiromed and Lupin) carry AB3 ratings, indicating therapeutic equivalence to the brand. The hormonal components are identical. The primary difference is in the placebo tablet iron formulation:

• Balcoltra (brand): Ferrous bisglycinate 36.5 mg
• Joyeaux (Xiromed generic): Ferrous fumarate 75 mg

For most patients, this difference in iron salt and dose is not clinically significant. However, patients with known sensitivities to specific iron formulations or those prone to GI side effects from iron may prefer one formulation over another.

Switching Within the Same Hormone Class

If neither the brand nor its generics are available, other levonorgestrel/ethinyl estradiol 0.1 mg/0.02 mg products (e.g., Aviane, Altavera, Aubra EQ, Afirmelle) provide the same hormonal contraception without the iron component. These are widely available and significantly less expensive.

Cross-Class Alternatives

For patients who may benefit from a different progestin or formulation:

• Yaz (drospirenone 3 mg/EE 0.02 mg): 24/4 regimen. FDA-approved for contraception, acne, and PMDD. Slightly higher VTE risk than levonorgestrel-containing products.
• Lo Loestrin Fe (norethindrone acetate 1 mg/EE 0.01 mg): Ultra-low-dose option with iron tablets. May suit patients sensitive to higher estrogen doses.
• Nuvaring (etonogestrel/EE vaginal ring): For patients open to non-oral administration.

A comprehensive comparison is available in the patient-facing article on alternatives to Balcoltra 28 Day.

Availability Picture

The availability challenge with Balcoltra is driven by market dynamics rather than a manufacturing crisis:

• Single-source manufacturing: Avion Pharmaceuticals remains the sole manufacturer of the brand product
• Pharmacy stocking patterns: Chain pharmacies prioritize high-volume generics. A branded product with limited prescription volume may not be kept in regular inventory
• Insurance formulary design: Most commercial and managed care plans tier generic levonorgestrel/EE products preferentially, reducing Balcoltra prescription volume and therefore pharmacy incentive to stock it
• Generic ramp-up: While two generics are FDA-approved, real-world distribution has been slow. Not all wholesalers carry the generics consistently

Cost and Access Considerations

Understanding the cost landscape helps you guide patients effectively:

• Retail cash price: $350–$450 per 28-day pack
• With GoodRx/SingleCare coupon: Approximately $73
• Manufacturer savings program: Eligible commercially insured and self-pay patients pay as little as $10/month. Avion covers up to $170 of out-of-pocket expense. Available at balcoltra.com. Phone: 1-877-838-3846
• ACA-compliant insurance: $0 copay for FDA-approved contraceptives
• Generic alternatives (e.g., Aviane): $9–$20 per pack with discount coupons

For patients with financial barriers, directing them to the manufacturer savings program or generic alternatives can significantly improve access. A patient-oriented savings guide is available at how to save money on Balcoltra 28 Day.

Tools and Resources for Your Practice

Several tools can help your practice and patients navigate availability issues:

Medfinder for Providers

Medfinder offers a provider-facing platform that allows your team to check real-time pharmacy availability for Balcoltra and other medications. This can be integrated into your prescribing workflow to proactively identify pharmacies with stock before sending a prescription.

Patient Resources

Consider sharing these resources with patients experiencing difficulty:

• How to find Balcoltra 28 Day in stock near you
• How to check if a pharmacy has Balcoltra in stock
• Balcoltra 28 Day side effects guide

Drug Interaction Reference

When considering alternatives, review key Balcoltra drug interactions. The most clinically significant interactions involve CYP3A4 inducers (rifampin, certain anticonvulsants, St. John's Wort) and HCV medications containing ombitasvir/paritaprevir/ritonavir (contraindicated). Lamotrigine levels are also reduced by COCs — an important consideration for patients with epilepsy.

Looking Ahead

The Balcoltra availability picture is expected to improve as generic distribution expands. In the meantime:

• Prescribe with pharmacy availability in mind — consider e-prescribing to pharmacies confirmed to have stock
• Have a pre-discussed backup plan with patients (e.g., "If the pharmacy can't fill Balcoltra, we'll switch to Aviane")
• Encourage patients to fill 90-day supplies when possible
• Use Medfinder for providers to streamline the process

Final Thoughts

Balcoltra 28 Day is a well-tolerated, low-dose contraceptive option that many patients prefer. While it's not in a formal FDA-listed shortage, real-world access challenges are genuine and require proactive management. By understanding the supply landscape, knowing the alternatives, and leveraging tools like Medfinder, you can ensure your patients maintain uninterrupted contraceptive protection.

For a companion patient guide, see the Balcoltra shortage update for patients. For provider-focused medication access strategies, visit our guide on helping patients find Balcoltra in stock.